The Swedish BioFINDER Study

The BioFINDER studies are independent and non-overlapping studies that have been initiated with the overarching aims to discover key mechanisms in Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders. These studies are designed to develop early and accurate diagnostic tests, identify novel treatment targets and help to understand the links between different pathologies and clinical symptoms.

BioFINDER
One

The first BioFINDER study, launched in 2008, focusing on the early stages of Alzheimer’s and Parkinson’s diseases and related disorders. It includes longitudinal assessments over a period of 6-10 years.

BioFINDER
Two

The second BioFINDER study, launched in 2017, is more comprehensive than BioFINDER One. It includes a larger number of study participants and cutting-edge brain imaging such as tau-PET in all study partcipants.

BioFINDER
Sleep

The BioFINDER Sleep study targeting prodromal Parkinson’s disease was initiated in 2021. It encompasses individuals with REM-sleep behavior disorder and those in the early stages of Parkinson’s disease.

BioFINDER
Preclinical AD

The study, launched in 2022, screens a general population with a blood test to detect preclinical (pre-symptomatic) Alzheimer’s disease. Its goals are to deepen our understanding of the initial stages of the disease and to optimize future primary and secondary prevention trials.

BioFINDER
Primary Care

This BioFINDER study was launched in 2020. It includes diverse patient populations with cognitive symptoms at different primary care centers. The main aim is to improve the diagnostic and prognostic work-up in primary care of neurocognitive disorders using blood biomarkers and brief cognitive tests.

BioFINDER
Memory Clinic

This BioFINDER study, launched in 2023, is complementary to the BioFINDER Primary Care study, but targets a Memory clinic population in a secondary care setting.

News articles

  • How dementia affects the brain’s ability to empathize

    Patients with frontotemporal dementia often lack the ability to feel empathy. A study at Lund University and the Karolinska...

    Read more...

  • Reading the signs of dementia

    In this Nature outlook the BioFINDER study group’s work on how blood tests are leading to earlier diagnosis, and...

    Read more...
More news...

X posts

Retweet on Twitter BioFINDER Retweeted
Oskar Hansson @OskarHansson9 ·
18 Nov 1858623327553946040

I was very grateful to meet the former Swedish prime minister Ingvar Carlsson today. He told about his experiences in taking care of his wife with Alzheimer’s disease for the last decade. He is such a fantastic and kind person! And still going strong when 90 years old.

Image for the Tweet beginning: I was very grateful to Twitter feed image.
Reply on Twitter 1858623327553946040 Retweet on Twitter 1858623327553946040 5 Like on Twitter 1858623327553946040 49 X 1858623327553946040
Retweet on Twitter BioFINDER Retweeted
Michael Okun @MichaelOkun ·
31 Oct 1851993297046376515

Which p-tau 217 assay for Alzheimer's was the best in comparative testing? This question is becoming an increasingly important one, as p-tau 217 has emerged as a possible single test which has great value. Noëlle Warmenhoven shares results in a fresh collaborative @Brain1878…

Image for the Tweet beginning: Which p-tau 217 assay for Twitter feed image.
Reply on Twitter 1851993297046376515 Retweet on Twitter 1851993297046376515 16 Like on Twitter 1851993297046376515 50 X 1851993297046376515
More posts...